Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
J Alzheimers Dis. 2023;95(1):237-249. doi: 10.3233/JAD-230290.
Conventional neuropsychological norms likely include cognitively unimpaired (CU) individuals with preclinical Alzheimer's disease (AD) pathology (amyloid-β, tau, and neurodegeneration) since they are based on cohorts without AD biomarkers data. Due to this limitation, population-based norms would lack sensitivity for detecting subtle cognitive decline due to AD, the transitional stage between healthy cognition and mild cognitive impairment. We have recently published norms for memory tests in individuals with normal cerebrospinal fluid (CSF) AD biomarker levels.
The aim of the present study was to provide further AD biomarker-based cognitive references covering attentional, executive function, linguistic, and visual processing tests.
We analyzed 248 CU individuals aged between 50-70 years old with normal CSF Aβ, p-tau, and neurodegeneration (t-tau) biomarker levels. The tests included were the Trail Making Test (TMT), Semantic Fluency Test, Digit and Symbol Span, Coding, Matrix Reasoning, Judgement of Line Orientation and Visual Puzzles. Normative data were developed based on regression models adjusted for age, education, and sex when needed. We present equations to calculate z-scores, the corresponding normative percentile tables, and online calculators.
Age, education, and sex were associated with performance in all tests, except education for the TMT-A, and sex for the TMT-B, Coding, and Semantic Fluency. Cut-offs derived from the current biomarker-based reference data were higher and more sensitive than standard norms.
We developed reference data obtained from individuals with evidence of non-pathologic AD biomarker levels that may improve the objective characterization of subtle cognitive decline in preclinical AD.
传统的神经心理学标准可能包括认知未受损(CU)的个体,这些个体有临床前阿尔茨海默病(AD)病理学(淀粉样蛋白-β、tau 和神经退行性变),因为它们是基于没有 AD 生物标志物数据的队列。由于这一限制,基于人群的标准将缺乏对 AD 导致的轻微认知衰退的敏感性,AD 是健康认知和轻度认知障碍之间的过渡阶段。我们最近发表了脑脊液(CSF)AD 生物标志物水平正常的个体记忆测试的标准。
本研究的目的是提供进一步的基于 AD 生物标志物的认知参考,涵盖注意力、执行功能、语言和视觉处理测试。
我们分析了 248 名年龄在 50-70 岁之间的 CU 个体,他们的 CSF Aβ、p-tau 和神经退行性变(t-tau)生物标志物水平正常。包括的测试有连线测试(TMT)、语义流畅性测试、数字和符号跨度、编码、矩阵推理、线定向判断和视觉拼图。当需要时,根据回归模型调整年龄、教育和性别进行了规范数据的开发。我们提供了计算 z 分数的方程、相应的规范百分位表和在线计算器。
除了 TMT-A 与教育相关,TMT-B、编码和语义流畅性与性别相关外,所有测试的年龄、教育和性别都与表现相关。从当前基于生物标志物的参考数据得出的截止值更高,更敏感。
我们开发了从具有非病理 AD 生物标志物水平证据的个体获得的参考数据,这可能有助于客观描述临床前 AD 中的轻微认知衰退。